Dehydroascorbic acid

Drug Profile

Dehydroascorbic acid

Latest Information Update: 17 Aug 2007

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Progenics Pharmaceuticals
  • Class Small molecules; Vitamins
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued CNS disorders; Stomatitis; Stroke

Most Recent Events

  • 26 Aug 2005 No development reported - Preclinical for CNS disorders in USA (unspecified route)
  • 26 Aug 2005 No development reported - Preclinical for Stroke in USA (unspecified route)
  • 26 Aug 2005 No development reported - Preclinical for Stomatitis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top